Merck Kgaa (MKGAF) Q3 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Dear ladies and gentlemen, welcome to the Merck Investor and Analyst Conference call on third quarter 2025. At any time during the conference, you can press star 1 1 to enter the queue for the question and answer session. As a reminder, all participants will be in a listen only mode. Please note this is our customer's request. This conference will be recorded. I'm now handing over to Florian Schroeder, Head of Investor Relations, who will lead you through this conference. Please go ahead, sir. Thank you so much, Sarah. And a sincere welcome to everyone joining the Merck Q3 25 results call. I'm Florian Schreder, the head of investor relations at Merck. I'm delighted to be here today with Belen Garrigio, our group CEO, and Helene von Röder, our group CFO. During the Q&A part of this call, we will also be joined by Kai Beckmann, CEO of Electronics and Deputy Chair of the Executive Board, Jean-Charles Wirth, CEO of LifeScience, and Danny Bazohar, CEO of Healthcare. In the first few minutes, we will walk you through the key slides of our presentation. After that, we will be happy to take your questions. Now, I will turn it over to Belen to get us started. Thank you, Florian. Good afternoon and welcome everybody to our Q3 earnings call. I am now on slide number five, starting with the highlights of this quarter. So as you have seen during the morning in Q3, we delivered solid organic growth across all three sectors. Organically, the group revenues increased by 5.2% and EBITDA pre went up by 8.8%. Life science delivered the strongest organic sales growth at 6%, followed by by our healthcare and electronics businesses, which both deliver solid organic growth of 5%. One key highlight of the quarter is the continuation of the strong performance of our process solutions busines...